Modern Management of Classical Hodgkin Lymphoma
Presented by Amy Goodrich, CRNP, and Jose D. Sandoval-Sus, MD
Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland; and Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System, Tampa, Florida
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2019;10(3):287–292 |
© 2019 Harborside™
Thanks to the introduction of checkpoint inhibitors, patients with classical Hodgkin lymphoma have a better chance at living longer with the disease. However, treatment-related side effects can impact quality of life in the short- and long-term. Amy Goodrich, CRNP, and Jose D. Sandoval-Sus, MD, provided strategies for preventing and mitigating these adverse events.
For access to the full length article, please sign in